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Skp2 E3 ligase is overexpressed in numerous human
cancers and plays a critical role in cell-cycle progres-
sion, senescence, metabolism, cancer progression,
and metastasis. In the present study, we identified
a specific Skp2 inhibitor using high-throughput
in silico screening of large and diverse chemical
libraries. This Skp2 inhibitor selectively suppresses
Skp2 E3 ligase activity, but not activity of other SCF
complexes. It also phenocopies the effects observed
upon genetic Skp2 deficiency, such as suppressing
survival and Akt-mediated glycolysis and triggering
p53-independent cellular senescence. Strikingly,
we discovered a critical function of Skp2 in positively
regulating cancer stem cell populations and self-
renewal ability through genetic and pharmacological
approaches. Notably, Skp2 inhibitor exhibits potent
antitumor activities in multiple animal models and
cooperates with chemotherapeutic agents to reduce
cancer cell survival. Our study thus provides pharma-
cological evidence that Skp2 is a promising target for
restricting cancer stem cell and cancer progression.
INTRODUCTION
Cancer is a complex disease characterized by multiple steps of
genetic alterations occurring primarily through mutations of
tumor suppressors and oncogenes. To date, chemotherapy and
radiotherapy represent two major options for cancer treatment
through inducing p53-dependent cellular senescence and
apoptosis (Vazquez et al., 2008). However, advanced cancers556 Cell 154, 556–568, August 1, 2013 ª2013 Elsevier Inc.often develop resistance to these treatments as they often lose
their p53 response due to frequent mutations on the p53 gene.
In this scenario, developing cancer treatment strategies via boost-
ing p53-independent senescence and/or apoptosis responses is
a key to the success of advanced cancer treatments. In addition,
targeting aerobic glycolysis has recently emerged as a promising
strategy for cancer therapies (Vander Heiden et al., 2009). Cancer
cells display elevated glycolysis irrespective of the presence or
absence of oxygen, which warrants cancer cell proliferation and
survival. Aerobic glycolysis is orchestrated by Akt, whose activa-
tion is achieved by its membrane translocation and subsequent
phosphorylation (Elstrom et al., 2004; Robey and Hay, 2009). As
our recent reports uncovered that distinct E3 ligases are utilized
to trigger nonproteolytic K63-linked ubiquitination of Akt (Chan
et al., 2012; Yang et al., 2009), targetingE3 ligase of Aktmay serve
as a promising strategy to tame cancer glycolysis.
Skp2 is an F box protein, constituting one of the four subunits
of the Skp1-Cullin-1-F-box (SCF) ubiquitin E3 ligase complex.
Earlier studies showed that Skp2 regulates apoptosis, cell-cycle
progression, and proliferation by promoting the ubiquitination
and degradation of p27 (Nakayama et al., 2004). However,
our recent report attributed a critical role of the Skp2 SCF
complex in triggering nonproteolytic K63-linked ubiquitination
of Akt (Chan et al., 2012). Overexpression of Skp2 is frequently
observed in human cancers, and ectopic expression of Skp2
promotes tumorigenesis in a prostate tumor xenograft model
(Hershko, 2008; Lin et al., 2009). Moreover, Skp2 overexpression
was found to promote cancer invasion and metastasis, whereas
its deficiency inhibits these processes (Chan et al., 2010a).
Using transgenic mouse models, we and others have illustrated
that Skp2 is required for cancer development in multiple tumor-
promoting conditions and that Skp2 deficiency triggers p53-
independent, p27-dependent cellular senescence/apoptosis
but inhibits Akt-mediated glycolysis (Chan et al., 2012; Lin
Figure 1. Identification of the Skp2 Inhibitor,
which Impairs Skp2 SCF E3 Ligase Activity
by Preventing Skp2-Skp1 Binding
(A) The identified potential binding pockets on the
interface of Skp2-Skp1 complex. Skp2 is shown as
molecular surface (gray for carbon, blue for nitro-
gen, and red for oxygen atoms). Skp1 is displayed
in purple/cyan ribbon and stick form. The cyan
region represents residues of Skp1 interacting with
Skp2 in the two pockets.
(B) In vitro Skp2-Skp1 binding assay with or
without compound #25.
(C) In vivo Skp2-Skp1 binding assaywith or without
compound #25 in PC3 cells.
(D) In vivo p27 ubiquitination assay in 293T cells
transfected with p27, His-Ub, along with Xp-Skp2
in the presence of DMSO or compound #25. WCE,
whole cell extracts.
(E) In vitro Skp2-mediated p27 ubiquitination assay
was performed with or without Flag-Skp2-SCF or
p27 in the presence of DMSO or compound #25.
(F) PC3 cells were treated with DMSO or com-
pound #25 at different doses for 24 hr and har-
vested for immunoblotting (IB) assay.
(G) In vivo Akt ubiquitination assay in 293T cells
transfected with various constructs in the presence
of DMSO or compound #25.
(H) In vitro Skp2-mediated Akt ubiquitination assay
was performed with or without Flag-Skp2-SCF or
GST-Akt in the presence of DMSO or compound
#25.
(I) LNCaP cells were serum starved in the absence
or presence of compound #25 for 24 hr, stimulated
with or without EGF, and harvested for IB assay.
See also Figure S1.et al., 2010; Wang et al., 2010). Collectively, these studies sug-
gest that targeting Skp2 is a promising strategy for cancer
treatment, thereby calling for an urgent need to develop specific
Skp2 inhibitors.
In this study, we aimed to develop a specific Skp2 small-
molecule inhibitor and tested its efficacy on tumor suppression.
Using structure-based high-throughput virtual screening tech-
nologies (Zhang, 2011), we have identified 25 compounds that
potentially interact with Skp2 to prevent its binding to Skp1.
Further experiments showed that one compound, called
compound #25, indeed binds to Skp2, prevents Skp2-Skp1
interaction, and inhibits Skp2 SCF E3 ligase activity, which
consequently suppresses the survival of cancer cells and cancer
stem cells. More importantly, compound #25 also exhibits
potent antitumor activity in animal studies. Our study therefore
offers convincing evidence that pharmacological inactivation of
Skp2 is a promising approach for cancer treatment.Cell 154, 556–5RESULTS
Identification of Skp2 Small-
Molecule Inhibitors Using High-
Throughput In Silico Screening
Approaches
The crystal structure of Skp2-SCF com-
plex (Protein Data Bank ID code 2AST)has demonstrated that Skp2 directly interacts with Skp1 via its
F box domain and indirectly associates with Cullin-1 and Rbx1
(Schulman et al., 2000; Zheng et al., 2002). Along the large
Skp2-Skp1 interaction interface (2,980 A˚2), some residues
contribute more significantly to their binding than others; these
residues are called hot spots. Based on our molecular visualiza-
tion, literature reports, and hot spot analysis, we found 19 resi-
dues on Skp2 in contact with Skp1. We grouped these critical
Skp2-Skp1 contact sites into two pocket-like and distinct
regions (Figure 1A). The first region (referred as pocket 1) is close
to the N terminus of Skp2 and is actually within the F box motif
including Trp97, Phe109, Glu116, Lys119, and Trp127. The
second region (referred as pocket 2), in proximity to the
C terminus of Skp2, is formed by the first leucine-rich repeat
(LRR) region and some residues from the F box (Figure 1A).
Therefore, inhibitors binding to these two pockets would poten-
tially prevent Skp2-Skp1 complex formation.68, August 1, 2013 ª2013 Elsevier Inc. 557
Based on the above-predicted potential binding pockets, we
performed high-throughput virtual screening with our rigorously
validated hit-identification workflow (Figure S1A) (Ahad et al.,
2011; Yadav et al., 2012). We screened 120,000 diverse
and commercially available chemical compounds using our
HiPCDock program (Zhang and Du-Cuny, 2009; Zhang et al.,
2008) and selected 25 hits that were predicted to bind to Skp2
(Figure S1A available online). Among them, 16 hits were pre-
dicted to interact with pocket 1, nine hits bind to pocket 2, and
two hits dock on both pockets. During the selections of these
hits, we considered not only the predicted binding affinities but
also various other drug-like properties such as solubility and
molecular weight. We propose that by interacting with either
(or both) of these two sites, our hits may block the binding of
Skp1 to Skp2 and thereby result in the deconstruction of the
Skp2 SCF complex (Figure 1A).
Skp2 Inhibitors Prevent Skp2-Skp1 Interactions
and Skp2 SCF E3 Ligase Activity In Vitro
To test our hypothesis generated in silico, we performed an
in vitro glutathione S-transferase (GST) pull-down assay to
assess which compounds from our 25 hits could prevent
Skp2 and Skp1 interactions. We found that seven of them
demonstrated strong inhibition of Skp2-Skp1 complex formation
at 20 mM (data not shown). Next, these seven compounds were
subjected to the in vitro Skp2-Skp1 binding assay at a lower
concentration (5 mM) in order to identify more potent Skp2
inhibitors (Figure 1B). Strikingly, we revealed that SZL-P1-41
(referred to as compound #25) could completely prevent Skp2-
Skp1 interactions at this concentration (Figure 1B). Consistently,
compound #25 impeded in vivo binding of Skp2 to Skp1 in a
dose-dependent manner (Figure 1C). It should be noted that
another compound, SZL-P1-35 (referred to as compound #22),
also reduced Skp2-Skp1 complex formation, albeit to a lesser
extent compared to compound #25 (Figure 1B). As the interac-
tion between Skp2 and Skp1 is a prerequisite for the integrity
of the Skp2 SCF complex and is crucial for executing its E3
ligase activity (Schulman et al., 2000; Zheng et al., 2002), our
data illustrate that the small molecules identified through the
in silico approach indeed prevent Skp2-Skp1 association.
The canonical role of the Skp2 SCF complex is primarily to
trigger ubiquitination and degradation of its protein substrates
(Chan et al., 2010b; Frescas and Pagano, 2008). Among all
canonical Skp2 substrates, p27 is the most well-characterized
target whose deficiency can rescue the phenotypes observed
in Skp2/ mice, indicating that p27 is a physiological substrate
for Skp2 (Nakayama et al., 2004). Since compound #25 dis-
played the highest efficacy in preventing Skp2-Skp1 complex
formation (Figure 1B), we further determined its effect on Skp2
SCF E3 ligase activity. In vivo and in vitro p27 ubiquitination
assays revealed that compound #25 inhibited Skp2-mediated
p27 ubiquitination (Figures 1D and 1E). Consistent with the p27
ubiquitination assay, we found that treatment with compound
#25 induced endogenous p27 protein expression in prostate
cancer cells (Figures 1F and 3E), recapitulating the phenotype
upon genetic Skp2 ablation (Carrano et al., 1999). Likewise, we
found that compound #25 also induced expression of p21 (Fig-
ures 1F and 3E), another Skp2 substrate (Bornstein et al., 2003).558 Cell 154, 556–568, August 1, 2013 ª2013 Elsevier Inc.Akt is a Skp2 substrate undergoing K63-linked poly-
ubiquitination (Chan et al., 2012). Consistent with the genetic
evidence that Skp2 regulates Akt ubiquitination, compound
#25 also inhibited Skp2-mediated Akt ubiquitination in vivo and
in vitro (Figures 1G and 1H). Since Skp2 is required for epidermal
growth factor (EGF)-mediated Akt phosphorylation and acti-
vation by triggering Akt ubiquitination, we next determined
whether our Skp2 inhibitor attenuated the process. As expected,
compound #25 profoundly inhibited EGF-mediated Akt phos-
phorylation and activation in various cancer cell lines (Figures
1I, S1B, and S1C). However, administration of compound #25,
similar to Skp2 deficiency, displayed no noticeable impact on
extracellular signal-regulated protein kinase activation (Figures
S1C and S1D), underscoring the important role of Skp2 in
selectively regulating EGF-mediated Akt signaling. It should be
noted that compound #25 not only abrogated Skp2-Skp1 com-
plex formation and Skp2 E3 ligase activity but also down-
regulated Skp2 protein expression at a higher dose (20 mM)
(Figures 1C, 1I, 3E, S1B, and S1C). Moreover, we uncovered
that compound #25 primarily caused downregulation of Skp2
at the protein level, not messenger RNA level, and this reduction
was partially rescued by proteasome inhibitor (Figures S1E and
S1F). Collectively, our data indicate that the pharmacological
Skp2 inhibition stabilizes p27 and p21 expression and inhibits
EGF-mediated Akt activation.
The Physical Binding of Skp2 Inhibitor to Skp2 Prevents
Skp2-Skp1 Complex Formation
The chemical structure of #25 disclosed in Figure 2A is charac-
terized by 1H, 13C-NMR and liquid chromatography-tandem
mass spectrometry (LC-MS/MS) analysis (Figure S2). To under-
stand how compound #25 interacts with Skp2 and prevents
Skp2-Skp1 complex formation, we analyzed our molecular
docking results. The benzothiazole substructure of #25 is
predicted to interact with residue Trp97, mainly via aromatic
stacking and polar contacts (Figure 2A). Interestingly, it is also
close to a hydrophobic pocket consisting of Trp97, Leu105,
Ile108, Phe109, and Trp127 (Figure 2A). Potentially, interaction
with this hydrophobic pocket can increase binding. The other
critical part of the inhibitor is the chromone moiety, which is
extended through the pocket formed by residues Asp98 and
Trp127 and has contacts with these residues via either hydrogen
bonds or hydrophobic/aromatic interactions. Interestingly, the
ethyl group on the phenol ring does not contribute significantly
to the inhibitor binding to Skp2; however, it extends out
into the region where Skp1 occupies when it binds to Skp2.
Therefore, this moiety is critical for preventing Skp1-Skp2
interactions, and removal of this ethyl group indeed abolished
activity, in agreement with our structure-activity relationship
studies (see SAR analysis section below). Additionally, the
piperidine group of #25 is critical for the inhibitor binding as it
interacts closely with Asp98 and Trp127.
We found that our pocket 2 inhibitors (such as inhibitor #5)
have very different core scaffolds. They bind to pocket 2 mainly
via interactions with Trp128, Ser132, Trp137, Gln158, and the
large leucine-rich hydrophobic pocket formed by the first and
second LRRs. The potent Skp2 inhibitor (inhibitor #25 in Fig-
ure 1B) was predicted to bind to pocket 1, but not pocket 2,
Figure 2. Skp2 Inhibitor Directly Interacts
with Skp2 at Trp97 and Asp 98 Residues
(A) Chemical structure of compound #25. 3-(1,3-
benzothiazol-2-yl)-6-ethyl-7-hydroxy-8-(1-pi-
peridinylmethyl)-4H-chromen-4-one (top). The
docking between compound #25 (magenta sticks)
and predicted pocket 1 of Skp2 (surface repre-
sentation). The residues in green lines form
hydrogen bonding/hydrophobic/aromatic stack-
ing interactions with compound #25. The yellow
dashed lines represent hydrogen bonds between
compound #25 and Skp2 (bottom).
(B) In vivo Skp2-Skp1 binding assay in 293T cells
transfected with Skp2 or its various mutants.
(C) In vivo p27 ubiquitination assay in 293T cells
transfected with various constructs in the pres-
ence of DMSO or compound #25.
(D) In vitro binding of Skp1with Skp2WTor various
mutants in the presence of DMSO or compound
#25.
(E) The extracted ion chromatography spectra
demonstrating the quantity of compound #25
bound to GST alone, GST-Skp2 WT, W97A
mutant, and D98A mutant (retention time
24 min.). The identity of the bound compound
was further confirmed by MS/MS analysis as
shown in Figure S3.
See also Figures S2 and S3.indicating that the pocket 1 within the F box motif is probably
more critical to the Skp2-Skp1 interaction. This notion is in
agreement with previous reports underscoring the importance
of F box motif in Skp2 SCF complex formation as well as Skp2
E3 ligase activity (Kim et al., 2003; von der Lehr et al., 2003).
Based on our modeling predictions, residues Trp97, Asp98,
Arg126, and Trp127 from Skp2 directly interact with compound
#25 (Figure 2A), while Pro101, Leu105, Ile108, and Phe109
residues are involved in Skp1 binding but do not significantly
contribute to the binding of #25. We next performed site-
directed mutagenesis to mutate these residues to alanine (Ala)
and determined which residues of Skp2 are critical for Skp2-
Skp1 binding and Skp2 E3 ligase activity. Of these residues,
only the Skp2 Trp97Ala, Asp98Ala, and Trp127Ala mutants still
retained their binding capacity to Skp1, whereas the rest of
other Skp2 mutants lost their interaction with Skp1 (Figure 2B).
The nature of the Arg126Ala mutant, which lost its ability to
bind to Skp1, precluded us to further examine the inhibitoryCell 154, 556–56effect of compound #25 on its E3 ligase
activity and binding to Skp1. For this
reason, we focused on Skp2 Trp97Ala,
Asp98Ala, and Trp127Ala to determine
the activity of compound #25 on their E3
ligase activity and interaction with Skp1.
While compound #25 abrogated E3 ligase
activity of wild-type (WT) Skp2 and
Skp2 Trp127Ala mutant, as determined
by in vivo p27 ubiquitination assay, it
failed to inhibit E3 ligase activity of
Skp2 Trp97Ala and Asp98Ala mutants,(Figure 2C). Furthermore, in vitro Skp2-Skp1 binding assays
revealed that although compound #25 prevented the interaction
between WT Skp2 and Skp1, it was unable to inhibit the binding
of Skp2 Trp97Ala and Asp98Ala mutants to Skp1 (Figure 2D).
These results suggest that Trp97 and Asp98 residues of Skp2
are critical sites for the binding of Skp2 to compound #25.
To corroborate this notion, we performed the in vitro binding
assay to compare the binding affinity of compound #25 to WT
Skp2 and Skp2 mutants (Trp97Ala and Asp98Ala) using
LC-MS/MS analysis. Of note, since the nature of recombinant
Skp2 protein was unstable in the absence of Skp1 (Li et al.,
2005), the GST-Skp2 WT, GST-Skp2 Trp97Ala, and GST-Skp2
Asp98Ala mutants subjected to LC-MS/MS analysis were
coexpressed, purified, and preformed complex with Skp1 (Fig-
ure S3A). In the preexisting Skp2-Skp1 complex, we clearly
detected that compound #25 readily bound to WT Skp2 but
failed to interact with the Trp97Ala and Asp98Ala mutants
(Figures 2E and S3B). Accordingly, our results underscore that8, August 1, 2013 ª2013 Elsevier Inc. 559
Figure 3. The Skp2 Inhibitor Specifically
Diminishes E3-Ligase Activity of Skp2-
SCF Complex, but Not Other F box SCF
Complexes
(A–D) 293T cells transfected with various con-
structs in the presence of DMSO or compound
#25 was treated with MG132 for 6 hr followed by
in vivo ubiquitination assay.
(E) LNCaP cells were treated with DMSO, Skp2
inhibitors, or MLN4924 for 24 hr and harvested for
IB assay.
See also Figure S4.the binding of compound #25 to Skp2 at Trp97 and Asp98 is
essential for blocking Skp2 E3 ligase activity.
Skp2 Inhibitor Specifically Suppresses the Skp2 SCF
Complex E3 Ligase Activity
To evaluate the specificity of the compound #25, we determined
whether compound #25 affects E3 ligase activity of other F box
proteins, such as Fbw7 and b-TrCP. Although compound #25
displayed a profound effect on Skp2-mediated ubiquitination
of p27 and Akt (Figures 1D, 1E, 1G, and 1H), it showed no
appreciable effects on Fbw7-mediated ubiquitination of c-Jun
and MCL-1 or b-TrCP-mediated ubiquitination of Snail and560 Cell 154, 556–568, August 1, 2013 ª2013 Elsevier Inc.IkBa (Figures 3A–3D). Consequently,
compound #25 selectively stabilized
expression of Skp2 substrates, including
p27, p21, and Notch1, but not Fbw7
substrates, such as c-Jun and MCL-1,
and b-TrCP substrates, such as Snail,
IkBa, and b-catenin (Figure 3E and S4A).
In contrast, treatment of MLN4924,
a potent inhibitor of the Nedd8 activating
enzyme that suppresses the activity
of Cullin-RING-based ubiquitin ligases
(Soucy et al., 2009), attenuated Fbw7-
mediated c-Jun ubiquitination (Figure
S4B). Additionally, substrates of SCF
complexes, such as c-Jun, p27, and
p21, were globally induced by MLN4924
(Figure 3E). Of note, MLN4924 also
induced expression of heat shock protein
27, indicating that MLN4924 elicits heat
shock response through globally inhibit-
ing the intracellular proteolytic response
(Figure 3E). These results underscore
that compound #25 selectively targets
E3 ligase activity of the Skp2-SCF com-
plex but not other SCF complexes.
Skp2 Inhibitor Restricts CancerCell
Survival through Triggering p53-
Independent Cellular Senescence
and Inhibiting Aerobic Glycolysis
Skp2 deficiency has a significant impact
on cancer cell proliferation and survivalby triggering cellular senescence, apoptosis, or inactivation of
glycolysis (Chan et al., 2011, 2012; Lin et al., 2010; Yokoi et al.,
2003). To test the therapeutic values of our Skp2 inhibitor, we
determined the impact of compound #25 on cancer cell pro-
liferation and survival. Indeed, compound #25 displayed potent
effects on cell viability of prostate cancer cell lines, including
PC-3 and LNCaP cells, but only slightly affected cell viability of
normal prostate epithelial PNT1A cells (Figures 4A and S5A).
Our results indicate that compound #25 has a great selectivity
on proliferation of prostate cancer cells over normal cells. We
extended this finding to other cancer cell lines by showing that
compound #25 favorably triggered cytotoxicity in tumorigenic
Figure 4. Inhibition of E3-Ligase Activity of
Skp2-SCF Complex Results in Cancer Cell
Death, Glycolysis Defects, and Cellular
Senescence
(A) Prostate cancer cells and normal epithelial cells
(PNT1A) were treated with various doses of com-
pound #25, followed by cell survival assay.
(B) Lung cancer cells and normal fibroblasts
(IMR90) were treated with various doses of com-
pound #25, followed by cell survival assay.
(C) PC3 cells were treated with or without com-
pound #25 for 4 days and harvested for senes-
cence assay.
(D and E) Lactate production was measured in
PC3 (D) or LNCaP (E) cells treated with DMSO,
LY294002, or compound #25.
(F) Apoptosis rate was determined in PC3 cells
treated with DMSO or compound #25.
(G and H) PC3 cells with or without Skp2 knock-
down (G) or PC3 cells stably expressed with Skp2
WT, W97A, or D98A mutants (H) were treated
with various doses of compound #25, followed by
cell survival assay. Cell survival percentage of
each stable cell lines treated with various doses
of compound #25 was normalized to that treated
with DMSO. Results are presented as mean
values ± SD. *p < 0.05; **p < 0.01.
See also Figures S5 and S6.lung cancer cells over nontumorigenic lung fibroblasts (Figures
4B and S5A). Moreover, we found that it elicited a potent sup-
pressive effect on the viability of other human-tumor-derived
cell lines, including H3255 (lung), H1299 (lung), Hep3B (liver),
andU2OS (osteocarcinoma), although different cancer cell types
exhibited variable sensitivity to the Skp2 inhibitor (Figure S5A).
We next determined the underlying mechanism by which
compound #25 regulates cancer cell proliferation and survival.
Consistent with the genetic Skp2 deficiency, our compound
#25 caused cell-cycle arrest at G2/M phase (Figures S5B–
S5D). Also, it triggered cellular senescence in p53-deficient
prostate cancer cells, indicating that pharmacological Skp2
inactivation induced a p53-independent senescence response
(Figure 4C). Moreover, Skp2 inhibition suppressed glycolysis
in two prostate cancer cell lines similar to Akt inactivation, as
determined by lactate production (Figures 4D and 4E). In addi-
tion, compound #25 caused higher apoptosis rates in cancerCell 154, 556–56cells, consistent with the observations
in Skp2-deficient cells (Figures 4F, S6A,
and S6B). These results, along with previ-
ous reports, illustrate that genetic and
pharmacological Skp2 inhibition attenu-
ates cancer cell proliferation and survival
possibly through regulating p53-inde-
pendent cellular senescence, aerobic
glycolysis, or apoptosis.
To determine whether the biological
effect of compound #25 is attributed to
Skp2 inhibition, we examined the effect
of compound #25 on cell survival incontrol- and Skp2-knockdown prostate cancer cells. While com-
pound #25 displayed a potent inhibitory effect on the viability
of control-knockdown cells in a dose-dependent manner, its
inhibitory effect is compromised upon Skp2 silencing (Figures
4G and S6C). We further demonstrated that ectopic expression
of Skp2 Trp97Ala or Skp2 Asp98Ala mutants, which are resistant
to the binding of compound #25, attenuated the inhibitory effect
of compound #25 on cell viability (Figures 4H and S6D). Taken
together, our results indicate that the action of compound #25
on cancer cell viability acts through its Skp2 inhibition and
binding.
Structure-Activity Relationships of Skp2 Inhibitor
To explore the structure-activity relationships (SARs) of our
Skp2 inhibitor, we have identified a series of compound #25
derivatives and evaluated their effects on in vitro Skp2-Skp1
binding (Figures 5A–5C). Our data demonstrate that the8, August 1, 2013 ª2013 Elsevier Inc. 561
Figure 5. The Structure-Activity Relation-
ship of Compound #25 Derivatives
(A and B) In vitro Skp2-Skp1 binding assay in
the presence of DMSO, compound #25, or its
derivatives.
(C) Structure-activity relationship (SAR) of com-
pound #25 and its derivatives. #25-5 is illustrated
separately due to its unique core structure.
(D) In vivo p27 ubiquitination assay in 293T cells
transfected with various constructs in the pres-
ence of DMSO, compound #25, or its derivatives
with MG132 treatment.
(E) PC3 cells were treated with various doses of
compound #25 or its derivatives, followed by cell
survival assay.benzothiazole at the R0 position of the chromone core is neces-
sary for binding, in agreement with our docking studies where
it forms pi-stacking interactions with residue Trp97. The change
of this group to a small thiazole ring caused the loss of activities
(compare #25 to #25-13 and #25-14 in Figures 5B and 5C), but
modifications to a comparable moiety such as benzoimidazole
retained the activities (#25-9). Apparently, the ethyl group on
the R1 position is critical as the activities are completely
abolished when it is changed to hydrogen (e.g., #25 compared
to #25-1 in Figures 5A and 5C). This is consistent with our
docking observations where this group occupies the space
where the Skp1 chain resides in the SCF complex. Our SAR
analysis indicated that any change to a big group (e.g., from
hydrogen to methyl or ethyl ester) at the R2 position is detri-
mental to the inhibitor binding (e.g., #25 compared to #25-10
and #25-12 in Figures 5B and 5C). This is also in agreement
with our structural observations where the R2 group has close
contacts with Skp2 and therefore a small group is favorable to562 Cell 154, 556–568, August 1, 2013 ª2013 Elsevier Inc.binding. Additionally, the chromone core
of compound #25 can be altered to
chromen-2-one, as compound #25-5
exhibited comparable ability to the lead
compound (#25) in preventing Skp2-
Skp1 interactions (Figures 5A and 5C).
We also found that modifications on the
R3 position, such as from the lead com-
pound #25 to #25-7 or #25-8, destroyed
the inhibitor activities. This is not surpris-
ing because in our docking models, we
observed that the piperidine ring is in a
channel formed by residues Asp98 and
Trp127. It is also in proximity to residue
Arg126. Therefore, a no-substituted ring
structure is preferred (Figures 5A and
5C). This also supports our site-directed
mutagenesis data that Asp98 is the
critical binding residue for Skp2 inhi-
bitors (Figures 2 and 5A–5C). It is worth
mentioning that the lack of the ethyl
group on #25-5 did not affect the activity
significantly (Figures 5A and 5C), because
this compound has a slightly alteredbinding pose due to its different core scaffold. As a matter of
fact, it seems that the piperidine moiety in #25-5 may partially
serve the function of the ethyl group to repel Skp1 away (data
not shown).
Based on the SAR analysis, both compounds #25-5 and
#25-9 disrupted in vitro Skp2-Skp1 binding as efficiently as
lead compound #25 (Figures 5A–5C). To determine whether
these two derivatives exhibited the same biological efficacy
as compound #25, we compared their roles in Skp2 E3 ligase
and cancer cell survival. As expected, they inhibited Skp2-
mediated p27 ubiquitination and cancer cell survival as pro-
foundly as compound #25 did, whereas other derivatives failed
to do so (Figures 5D and 5E). These data, along with mutagen-
esis results (Figures 2 and 5), collectively illustrate that the
stable interactions with the Trp97 and Asp98 residues are
indispensible for the activities of Skp2 inhibitors in suppressing
Skp2-Skp1 binding, Skp2 E3 ligase activity, and cancer cell
survival (Figures 2 and 5).
Figure 6. Skp2 Inactivation Diminishes
Cancer Stem Cell Properties
(A) Populations of ALDH+ cells were determined
by FACS analysis in PC3 cells treated with vehicle
or compound #25.
(B) Populations of ALDH+ cells were determined
by FACS analysis in PC3 cells with control or Skp2
knockdown.
(C) Populations of ALDH+ cells were determined
by FACS analysis in PC3 cells with control or Skp2
knockdown treated with vehicle or compound #25.
(D) Populations of ALDH+ cells were determined
by FACS analysis in PC3 cells with DMSO or
LY294002.
(E) Populations of ALDH+ cells were determined
by FACS analysis in LNCaP cells treated with
DMSO, LY294002, or compound #25.
(F and G) Prostate sphere-formation assay in
PC3 (F) and LNCaP (G) cells treated with DMSO,
LY294002, or compound #25. Results are2 pre-
sented as mean values ±SD; **p < 0.01.Skp2 Inactivation Inhibits Cancer Stem Cell Populations
and Self-Renewal Capability
Like stem cells, cancer stem cells (CSCs, also known as cancer-
initiating cells) express similar surface markers and possess
asymmetric cell division and self-renewal capability. CSCs
have recently emerged to play roles in cancer initiation and
progression (Rajan and Srinivasan, 2008). However, how CSC
populations and self-renewal ability are regulated remains largely
unclear. A recent report illustrated that glycine decarboxylase
drives CSC properties and tumorigenesis by promoting aerobic
glycolysis (Zhang et al., 2012). In addition to glycolysis, cellular
senescence through telomere shortening has been linked to
restrain of CSC populations (Marian et al., 2010). In light of these
observations, we reasoned that targeting aerobic glycolysisCell 154, 556–56pathways and inducing cellular senes-
cence may reduce CSC self-renewal and
favor chemotherapy sensitivity.
As Skp2 regulates p53-independent
cellular senescence and Akt-mediated
aerobic glycolysis, we determined
whether Skp2 inactivation has any effect
on CSC populations and their self-
renewal capability. Both Skp2 knock-
down and pharmacological Skp2 inacti-
vation in prostate cancer cells reduced
CSC populations, similar to what inhibi-
tion of the PI3K-Akt pathway did (Figures
6A–6E). Moreover, we found that while
compound #25 reduced the population
of prostate CSCs in a dose-dependent
manner, it failed to do so upon Skp2
silencing. These data underscore the
fact that Skp2-regulated CSC pool size
strictly depends on Skp2 (Figure 6C).
The prostate sphere formation assay
also revealed that Skp2 inhibition by ge-netic and pharmacological approaches markedly suppressed
the self-renewal ability of prostate CSCs; so did Akt inactivation
(Figures 6F and 6G). These results uncover a crucial role of
Skp2 in regulating CSC population and self-renewal capability.
The existence of CSCs is the major cause of cancer cell
resistance to chemotherapy (Koch et al., 2010). As genetic
and pharmacological Skp2 inactivation effectively restricts
CSC properties in prostate cancer cells (Figure 6), we reasoned
that our Skp2 inhibitor may sensitize cancer cell response to
chemotherapy agents, such as doxorubicin (Dox) and cyclo-
phosphamide (CPA). As expected, Skp2 inhibition increased
the efficacy of Dox and CPA on prostate cancer cells (Figures
7A and 7B), indicating that our Skp2 inhibitor may overcome
chemoresistance via eradicating CSC populations.8, August 1, 2013 ª2013 Elsevier Inc. 563
Pharmacological Skp2 Inactivation Exhibits Strong
Antitumor Activities In Vivo
Escape of cellular senescence and promotion of aerobic glycol-
ysis are two critical hallmarks of cancer progression and cancer
drug resistance, and targeting these two events is therefore an
ideal approach to cancer treatment. Since we have shown that
compound #25 effectively triggers senescence and inhibits
glycolysis, we then examined the efficacy of compound #25 on
suppression of pre-existing tumors in vivo. Figures 7C and 7D
demonstrate that compound #25 displayed a potent effect on
inhibiting prostate and lung tumor growth in vivo. Importantly,
compound #25 restricted tumor growth in a dose-dependent
fashion. Of note, compound #25 resulted in a dose-dependent
decrease in Skp2 levels in tumor tissues and correlated with
the in vivo upregulation of p27, p21, and apoptosis and the
downregulation of cancer cell proliferation, Akt activity, and
Glut1 (glucose transporter 1) expression, which are both critical
regulators for glycolysis (Figures 7D–7F, S7A, and S7B). The
pharmacokinetic analysis further revealed that the concentration
of compound #25 reached maximum levels in blood 1 hr after
intraperitoneal administration (Cmax was 1,428 ± 1,185 ng/ml),
maintained up to 70% of the compound for 6 hr, but quickly
declined afterward with a terminal concentration of 126 ±
48 ng/ml 24 hr after administration (Figure S7C). Of note, com-
pound #25 indeed reached tumors within 1 hr with a concentra-
tion of 4,787 ± 1,967 ng/g and slowly declined in tumor tissues,
and about 1,164 ± 494 ng/ml of compound #25 remained in
tumor tissues 24 hr after initial administration (Figure S7C).
Our results collectively provide convincing pharmacological
evidence that Skp2 targeting represents a promising strategy
and open an avenue for the treatment of human cancers.
DISCUSSION
Characterization of Modes of Action of the Specific
Skp2 Inhibitor
Skp2 is frequently upregulated in human cancer and plays a
critical role in cancer development by targeting p27 protein
degradation or activating Akt signaling and therefore is regarded
as a drug target. Recently, small molecules targeting the p27
pathways were identified: a small-molecule cpdA targeting p27
ubiquitination (Chen et al., 2008) and small molecules interrupt-
ing Skp2-p27 binding (Wu et al., 2012). Although cpdA could
cause cell growth defects in vitro, it is unclear how cpdA regu-
lates p27 ubiquitination and whether it has any direct effect on
Skp2 activity. Small-molecule inhibitors identified by Timothy
Cardozo’s group were shown to interrupt Skp2-p27 binding
but retain the Skp1-Skp2 complex formation, suggesting these
inhibitors presumably will not affect Skp2 E3 ligase activity.
Furthermore, the biological efficacy on tumor growth of either
cpdA or the inhibitors identified by Timothy Cardozo’s group
remains elusive. In our study, we found that compound #25 is
a specific Skp2 inhibitor by directly binding to the F box motif
of Skp2, thus preventing Skp2-Skp1 interactions and subse-
quently abrogating Skp2 E3 ligase activity toward ubiquitination
of p27 and Akt in vivo. Interestingly, our data revealed that Skp2
inhibitor #25, when used at higher doses, not only prevents
Skp1-Skp2 complex formation but also induces Skp2 degrada-564 Cell 154, 556–568, August 1, 2013 ª2013 Elsevier Inc.tion in a manner partially dependent on the proteasome, indi-
cating that the Skp2 degradation induced by the Skp2 inhibitor
is likely caused by its effect on preventing Skp1-Skp2 complex
formation. This notion is consistent with the fact that recombi-
nant Skp2 protein becomes unstable in the absence of Skp1
(Li et al., 2005). Remarkably, compound #25 does not affect
activity of other F box proteins, including Fbw7 and b-TrCP.
Future studies are required to characterize the impact of the
Skp2 inhibitor on other F box proteins.
It should be noted that while Skp2 inhibitor #25 could prevent
theassemblyofSkp2-Skp1complex in vitroand in vivo (Figure1B
and 1C), it failed to disrupt the pre-existing Skp2-Skp1 complex
in vitro (data not shown). However, we noticed that in the pre-
formed Skp2-Skp1 complex in vitro, compound #25 could still
specifically bind to Skp2 (Figures 2E and S3) and inactivate
Skp2 activity as determined by in vitro ubiquitination of p27 and
Akt (Figures 1E and 1H). Moreover, we found that compound #25
binds to Trp97 and Asp98 residues of Skp2 and such binding
is required for its actions (Figures 2C and 4H). Collectively, our
results suggest that two modes of action by Skp2 inhibitor #25
are likely operating in cells. We propose that the primary mecha-
nism of Skp2 inhibitor #25 on Skp2 E3 ligase activity is to prevent
the assembly of newly synthesized Skp2-Skp1 complex by
binding to Skp2. Another mode of #25 action against Skp2
activity is through its binding to preformed Skp1-Skp2 complex.
Nevertheless, both actions of compound #25 on the assembly of
newly synthesized Skp2-Skp1 complex or pre-existing Skp2-
Skp1 complex are attributed to specific Skp2-compound #25
binding, thereby inactivating its E3 ligase activity.
Molecular Docking and SAR Analysis Reveal Crucial
Structural Features for Skp2 Inhibitor Activity
The high-throughput virtual screening employed in the current
study allowed us to identify compound #25 as a specific Skp2
inhibitor and reveals its structural binding mechanism (Fig-
ures 1 and S1A) to Skp2. Based on the prediction, it was
observed that Trp97 is the essential residue that directly inter-
acts with the benzothiazole substructure of compound #25.
We also found that Leu105, Ile108, Phe109, and Trp127 form a
hydrophobic pocket that is critical for Skp1 binding and may
be used to design more potent inhibitors than compound #25.
In support of this notion, our mutagenesis data showed that
the mutations of these residues to alanine abolished the Skp2-
Skp1 interaction. In agreement with the prediction by molecular
modeling, Skp2 Trp97Ala and Asp98Ala mutants failed to
interact with compound #25, thereby displaying resistance to
our inhibitors. Furthermore, derivatives of compound #25 with
a bulky group at the R1 but not the R2 position are favorable to
the inhibitory activities of interfering with Skp2-Skp1 complex
formation and Skp2 activity. The docking and SAR analysis of
Skp2 inhibitors not only is consistent with our experimental
notion that Trp97 and Asp98 residues are indispensible for the
binding of inhibitors but also provides important information to
guide our future chemical optimization of lead compound #25.
Skp2 Regulates CSC Population and Functions
CSCs are regarded as seeds for cancer initiation, progression,
and relapse after chemotherapy (Rajan and Srinivasan, 2008).
Figure 7. Skp2 Inhibitor Heightens Cancer Cell Sensitivity to Chemotherapy and Suppresses Tumor Growth in Human Tumor Xenografts
(A and B) PC3 cells in the absence or presence of compound #25 were treated with Dox (A) or CPA (B), followed by cell survival assay.
(C and D) Nudemice bearing A549 (C) or PC3 (D) tumor xenografts were administration with or without compound #25 via i.p. injection. Mean tumor volumes ±SD
are shown; n = 6 mice per group.
(E and F) The quantification results (E) and representative images (F) of histological analysis of p27, p21, pAkt, and Glut1 in PC3-induced tumor xenografts. ‘‘Low’’
indicates 40 mg/kg and ‘‘high’’ indicates 80 mg/kg of compound #25 was injected into mice. Scale bar indicates 100 mm.
(G) The working model depicts how Skp2 inhibitor prevents Skp2-SCF complex formation and results in tumor suppression. Results are represented as mean
values ±SD. *p < 0.05; **p < 0.01.
See also Figure S7.
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Thus, orchestrating the populations and functions of CSCs may
help thwart cancer progression and improve the efficacy of
current chemotherapy agents. Our findings using the genetic
(Skp2 knockdown) and pharmacological (Skp2 inhibitor)
approaches demonstrated that Skp2 inactivation reduces CSC
populations and their ability to form prostate spheres (Figure 6),
suggesting that Skp2 is a previously uncharacterized, key
regulator for the maintenance of CSCs. Given that Skp2
targeting attenuates aerobic glycolysis and induces cellular
senescence in cancer cells, our study implies that targeting
glycolysis and inducing cellular senescence pathways may
represent attractive strategies for CSC elimination.
Pharmacological Skp2 Inhibition in the Treatment
of Cancer and Other Diseases
We discovered specific Skp2 inhibitors targeting Skp2 SCF
complex formation by using in silico high-throughput screening
of a large chemical database. These inhibitors were validated
for their effects on preventing Skp2-Skp1 interaction, inhibiting
Skp2 SCF E3 ligase activity toward ubiquitination of p27 and
Akt, and repressing in vivo tumor growth. Importantly, we also
revealed a critical function of Skp2 in governing CSC properties
(Figure 7G). Our study provides proof of principle that pharma-
cological Skp2 inactivation could profoundly restrict cancer
developments in various cancer models and confer sensitivity
to chemotherapy, supporting the notion that Skp2 is a promising
drug target for human cancers.
Not only does Skp2 regulate glucose metabolism and there-
fore endow cancer development, but it also plays an essential
role in other metabolic disorders, such as obesity, evidenced
by a previous report demonstrating that Skp2 ablation protects
mice from developing obesity through reducing adipocyte
proliferation (Sakai et al., 2007). Having shown the promise of
the Skp2 inhibitor in suppressing glycolysis, it would be inter-
esting to test whether Skp2 inhibitors could be applied to
antiobesity therapy in the future. As such, our current study
opens up an avenue in multiple therapeutic areas that can
translate basic findings into the clinical setting, thereby offering
great opportunity and impact on the treatment of cancer as
well as other metabolic disorders.
EXPERIMENTAL PROCEDURES
Cell Culture and Reagents
293T, PC3, A549, H460, H1299, Hep3B, and U2OS cells were cultured in
Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum
(FBS) while LNCaP and H3255 were cultured in RPMI-1640 medium con-
taining 10% FBS. (His)6-ubiquitin, GST-Akt, and HA-Akt constructs have
been described previously (Yang et al., 2009). Flag-Skp2 was a gift from
Dr. W. Wei. GST-Skp2 Trp97Ala (W97A) and GST-Skp2 Asp98Ala (D98A) mu-
tants were generated in pGEXSkp2DN-Skp1D, a gift from Dr. B.A. Schulman,
by site-directed mutagenesis assay according to the manufacturer’s standard
procedures (Stratagene). Compound #25 and its analytical data, including
1H, 13C-NMR and LC-MS/MS analysis, were obtained from ChemBridge.
LY294002 was purchased from Cell Signaling.
LC-MS/MS Analysis of the In Vitro Binding between Skp2
and Skp2 Inhibitor
GST-Skp2 W97A and GST-Skp2 D98A mutants used for demonstrating
#25-Skp2 interaction (Figure 2E) were generated in pGEXSkp2DN-Skp1D566 Cell 154, 556–568, August 1, 2013 ª2013 Elsevier Inc.bicistronic coexpression constructs. Subsequently, the GST-Skp2 WT, GST-
Skp2 W97A, and GST-Skp2 D98A mutants were coexpressed, purified, and
formed complex with Skp1 (D38–44 amino acids) as described previously
(Li et al., 2005). The purified proteins were incubated with compound #25
overnight at 4C, and the GST tags were thrombin-cleaved and pulled down
by glutathione Sepharose beads (Invitrogen). The untagged protein samples
were pH-adjusted by adding 50 mM ammonium bicarbonate and digested
by adding 200 ng modified trypsin (sequencing grade, Promega) for 18 hr at
37C. The resulting peptides and compound were analyzed by LC-MS/MS
on an Orbitrap-Elite mass spectrometer (Thermo Scientific). Proteins were
identified by database searching of the fragment spectra against the
SwissProt (EBI) protein database using Mascot (volume 2.3, Matrix Science).
Typical search settings were as follows: mass tolerances, 10 ppm precursor,
0.8d fragments; variable modifications, methionine sulfoxide, pyro-glutamate
formation; up to two missed cleavages. The extracted ion chromatograms
(XICs) for the bound compounds were examined and peak heights were
analyzed and quantified by using Qual Browser (Thermo). The identity of
the bound compound shown in XIC (Figure 2E) was further confirmed by
MS/MS analysis as shown in Figure S3B.
In Vivo Drug Treatment in the Preclinical Tumor Model
Nude mice bearing A549 xenograft tumors (around 100 mm3) were adminis-
trated with vehicle or 80 mg/kg of compound #25 through intraperitoneal
(i.p.) injection, while mice bearing PC3 xenograft tumors (around 180 mm3)
were administrated with vehicle, 40 mg/kg, or 80 mg/kg of compound #25,
respectively, on a daily basis. Tumor size was measured weekly with a caliper,
and tumor volume was calculated by using the standard formula L 3 W2 3
0.52, where L and W are the length and width, respectively. For mouse
pharmacokinetic studies, nude mice bearing PC3 xenograft tumors (around
200 mm3) were administrated with 80 mg/kg of compound #25 through i.p.
injection with a single dose. Plasma and tumor samples were then harvested
from euthanized mice at the indicated time and flash-frozen in liquid nitrogen.
Then 100 ml of plasma was incubated with 23 volume of acetonitrile, mixed,
and then centrifuged at maximum speed for 3–5 min. Tumor tissues
were weighed, added with methanol to a weight/volume concentration of
25 mg/ml, and homogenized on ice using a handheld tissue homogenizer.
Then 100 ml of tissue homogenate was mixed with 100 ml of 0.2% formic
acid and 100 ml of acetonitrile for 5 min, incubated on ice for an additional
10 min, and centrifuged. Afterward, 200 ml of clear supernatant from plasma
or tumor homogenate was subjected to an HPLC vial for analysis by LC-MS/
MS on a Waters Acquity triple-quadrupole mass spectrometer to determine
the concentration of compound #25. All animal experiments were performed
under IACUC approval protocol.
Immunohistochemistry
All of the immunohistochemistry experiments dealing with human subjects
were performed under protocol approved by the institutional review board
of Chi-Mei Medical Center. For detailed information regarding immunohisto-
chemistry, please refer to the Extended Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
seven figures and can be found with this article online at http://dx.doi.org/
10.1016/j.cell.2013.06.048.
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